Grifols SA
OTC:GIKLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Grifols SA
OTC:GIKLY
|
ES |
|
A
|
Aurubis AG
XMUN:NDA
|
DE |
Grifols SA
Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines. Its customers are hospitals, clinics, pharmacies, blood banks, and medical laboratories. Grifols makes money by selling finished therapies, diagnostic reagents, and testing instruments, and by supplying products and services tied to plasma collection and blood testing. A large part of the business depends on turning donated plasma into specialized treatments that are hard to make and heavily regulated. What makes Grifols different is that it sits in several parts of the healthcare value chain at once. It collects plasma, processes it into medicines, and also sells diagnostic equipment that helps screen blood and support laboratory testing. That mix gives it a role both as a drug maker and as a supplier to the blood and diagnostics industry.
Grifols is a healthcare company that makes medicines and diagnostic products from human plasma. Its main products are plasma-derived therapies used to treat immune disorders, bleeding conditions, and other serious illnesses, along with diagnostic test systems and blood-typing tools used in labs and hospitals. It also runs plasma collection centers, which supply the raw material for its medicines.
Its customers are hospitals, clinics, pharmacies, blood banks, and medical laboratories. Grifols makes money by selling finished therapies, diagnostic reagents, and testing instruments, and by supplying products and services tied to plasma collection and blood testing. A large part of the business depends on turning donated plasma into specialized treatments that are hard to make and heavily regulated.
What makes Grifols different is that it sits in several parts of the healthcare value chain at once. It collects plasma, processes it into medicines, and also sells diagnostic equipment that helps screen blood and support laboratory testing. That mix gives it a role both as a drug maker and as a supplier to the blood and diagnostics industry.
In line: Grifols said Q1 2026 results were in line with expectations and full-year 2026 guidance remains on track.
Biopharma led: Biopharma was the main growth driver, with immunoglobulins delivering double-digit growth and U.S. demand still strong.
China headwind: Albumin sales fell in China because of pricing and market pressure, but management said hospital pricing has started to stabilize and expects improvement later in the year.
Plasma shift: The company framed Egypt as a major strategic lever that should lower cost per liter, improve supply security and support margin expansion.
Balance sheet: Grifols said refinancing materially strengthened liquidity and removed near-term refinancing risk, while cash interest is still expected to be at or below 2025 levels.
Diagnostics optionality: Diagnostics was held back by the Quidel Ortho dissolution, but management said the business is still on track and the new Barcelona platform remains a key launch later in 2026.
